Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis.

Frontiers in immunology - 1 Jan 2024

Sugiyama Naonobu, Terry Frances E, Gutierrez Andres H, Hirano Toshitaka, Hoshi Masato, Mizuno Yasushi, Martin William, Yasunaga Shin'ichiro, Niiro Hiroaki, Fujio Keishi, De Groot Anne S

Abstract excerpt

Hypothesis: While conventional in silico immunogenicity risk assessments focus on measuring immunogenicity based on the potential of therapeutic proteins to be processed and presented by a global population-wide set of human leukocyte antigen (HLA) alleles to T cells, future refinements might adjust for HLA allele frequencies in different geographic regions or populations, as well for as individuals in those...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Biological Products

Share to Gene Frequency

Share to HLA-DR Antigens

Source

Open in PubMed Open full text

Identifiers

PMID: 38812524
DOI: 10.3389/fimmu.2024.1377911
PMCID: PMC11134572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis.PMID 38812524Read ↗

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesSemantic proximity Read ↗

Statistical Methodology for Qualification of a Non-Clinical Risk Assessment Peptide:T Cell Proliferation Assay to Support Decision MakingSemantic proximity Read ↗

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritisSemantic proximity Read ↗

Relationship Between Potential Aggregation-Prone Regions and HLA-DR-Binding T-Cell Immune Epitopes: Implications for Rational Design of Novel and Follow-on Therapeutic AntibodiesSemantic proximity Read ↗

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancementsSemantic proximity Read ↗

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model ApplicationsSemantic proximity Read ↗

Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.Semantic proximity Read ↗

Predicting population coverage of T-cell epitope-based diagnostics and vaccines.Semantic proximity Read ↗

Authors' Response to Comment on "When Genes Meet Gels: Computational Immunogenetics of Dermal Fillers and Stratified Risk of Immune and Fibrotic Reactions Across Compositions and Genotypes".Semantic proximity Read ↗

Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>Semantic proximity Read ↗

A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM).Semantic proximity Read ↗

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.